Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2

Bioorganic & Medicinal Chemistry Letters
2001.0

Abstract

Highly potent CCR3 antagonists have been developed from a previously reported series of phenylalanine ester-based leads. Solution-phase, parallel synthesis optimization was utilized to identify highly potent, functional CCR3 antagonists.

Knowledge Graph

Similar Paper

Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2
Bioorganic & Medicinal Chemistry Letters 2001.0
Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1
Bioorganic & Medicinal Chemistry Letters 2001.0
Design and synthesis of novel CCR3 antagonists
Bioorganic & Medicinal Chemistry Letters 2003.0
Synthesis and structure–activity relationship of benzetimide derivatives as human CXCR3 antagonists
Bioorganic & Medicinal Chemistry Letters 2008.0
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist
Bioorganic & Medicinal Chemistry 2011.0
Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton
ACS Medicinal Chemistry Letters 2018.0
Development of N-(4-Phenoxyphenyl)benzenesulfonamide Derivatives as Novel Nonsteroidal Progesterone Receptor Antagonists
ACS Medicinal Chemistry Letters 2016.0
Isolation and Structures of Novel Fungal Metabolites as Chemokine Receptor (CCR2) Antagonists
The Journal of Antibiotics 2005.0
Discovery of a Novel Series of Biphenyl Benzoic Acid Derivatives as Potent and Selective Human β<sub>3</sub>-Adrenergic Receptor Agonists with Good Oral Bioavailability. Part I
Journal of Medicinal Chemistry 2008.0
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists
Journal of Medicinal Chemistry 1987.0